Plasma copeptin was associated with markers of kidney function at baseline (eGFR, UAC), and with the decline of kidney function and the progression of CKD during follow-up in both cohorts, as previously reported in people with type 1 or type 2 diabetes [10, 13, 36], as well as in the general population [7, 11, 33]. The gene discussed is AVP; the disease is type 2 diabetes mellitus.